Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir in Chronic Hepatitis C (Prior Trial Participants)
NCT00943761Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Primary completion
- May 2013
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of vaniprevir in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoints: Adverse Event at 72 weeks, Serious Adverse Event at 72 weeks and 2 more. Started Oct 2009; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00943761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943761.